Equities research analysts expect Nivalis Therapeutics, Inc. (NASDAQ:ALPN) to report earnings of ($0.28) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Nivalis Therapeutics’ earnings. Nivalis Therapeutics posted earnings of ($1.92) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 85.4%. The firm is expected to issue its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Nivalis Therapeutics will report full year earnings of ($3.44) per share for the current fiscal year, with EPS estimates ranging from ($4.31) to ($2.96). For the next financial year, analysts anticipate that the company will post earnings of ($1.34) per share, with EPS estimates ranging from ($2.00) to ($0.60). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Nivalis Therapeutics.

Several analysts have recently commented on ALPN shares. Zacks Investment Research cut Nivalis Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Ladenburg Thalmann Financial Services started coverage on Nivalis Therapeutics in a report on Thursday, July 27th. They set a “buy” rating and a $17.00 target price on the stock. ValuEngine upgraded Nivalis Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Finally, Cowen and Company restated a “hold” rating on shares of Nivalis Therapeutics in a report on Wednesday, April 19th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.81.

WARNING: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/15/0-28-eps-expected-for-nivalis-therapeutics-inc-alpn-this-quarter.html.

Shares of Nivalis Therapeutics (NASDAQ:ALPN) traded down 5.00% during trading on Tuesday, hitting $8.36. 55,198 shares of the stock were exchanged. Nivalis Therapeutics has a 12-month low of $8.00 and a 12-month high of $37.40. The stock has a 50-day moving average of $9.28 and a 200 day moving average of $9.83. The stock’s market cap is $11.20 million.

In other news, insider Value Fund L. P. Biotechnology purchased 78,858 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The shares were acquired at an average price of $2.30 per share, for a total transaction of $181,373.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Value Fund L. P. Biotechnology purchased 17,806 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $40,063.50. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 288,964 shares of company stock worth $660,495. 3.00% of the stock is owned by company insiders.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Get a free copy of the Zacks research report on Nivalis Therapeutics (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.